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EDITORIAL
Small-Cell Lung Cancer, Getting Smaller
But Still Difficult to Treat
Craig P. Carden, MBBS, FRACP, and Mary E. R. O’Brien, MD, FRCP
Although small-cell lung cancer (SCLC) is chemosensitive, relapses invariably occurand the median survival remains at best 14.5 months for limited stage and 8.4 months
for extensive stage disease.1 Response rates to second-line chemotherapy are higher if
relapse occurs after a long period since first line therapy.2 Thus there is general nihilism
about second-line treatment for relapsed SCLC. Even in the first line setting attempts to
improve response rates and survival by adding new chemotherapeutic agents, giving
chemotherapy for longer, at higher doses, or even with stem-cell support have all proved
discouraging.3
A couple of recent reported positive studies have therefore been welcomed. The
publication of a trial4 in patients with extensive stage small-cell lung cancer showed that
the use of prophylactic cranial irradiation after chemotherapy decreased the incidence of
brain metastases and gave a survival and symptomatic benefit, (with a 1 year survival rate
of 13.3% in the control group compared with 27.1% in the treated group, (p  0.003,
HR0.68)). This has come as something of a surprise, suggesting that the more of this
disease we can control even with simple strategies the better the outcome.
The other major recent report was of oral topotecan as second-line treatment for
small-cell lung carcinoma in a randomized phase III study showed an improved survival
compared with best supportive care.5 This improvement was noted in all subgroups
irrespective of previous responsiveness to first line chemotherapy and in a way suggests
that this categorization is no longer clinically useful. However, the study was criticized by
some because offering some groups of patients best supportive care only was considered
unrealistic. Given the unlikely event of this trial design being repeated for ethical reasons,
it is now supportive to have, in the article by Froeschl et al. in this issue6 a retrospective
study confirming the prospective trial results!
The authors reviewed 192 patients with small-cell lung carcinoma at their institution
who relapsed in a 5-year period, and compared their outcomes with those who did not
receive chemotherapy. They analyzed the characteristics of both groups, the chemother-
apy they received, and their response to treatment. Their findings, in summary, are that
32% of the patients who had relapsed disease actually received second-line chemotherapy,
those patients who receive second-line chemotherapy do better than the patients who do
not, and that performance status predicts for response. In addition, as was found in the
prospective study quoted above, both patients who had received chemotherapy relatively
recently, and those who had a longer period off treatment benefited from retreatment.
Being retrospective, it is open to criticisms, in particular to that of selection bias in
comparing outcomes of patients well enough to be treated with second-line chemotherapy
to the two-thirds of patients who were not well enough. However, the figure of 30% of
patients being suitable for retreatment was also the figure in Sundstrom’s study of cross
over chemotherapy at first relapse1 indicating that chemoresistant patients gained benefit
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from second-line chemotherapy similar in magnitude to par-
ticipants in the randomized phase III study of oral topotecan.5
This article demonstrates that a retrospective approach can
still yield useful information.
What new information does this study provide? As
opposed to the relatively rigidly defined populations of pro-
spective trials, this study shows the outcome of an unselected
population, and potentially reflects a more “real world” clin-
ical scenario or what could also be called an audit. It supplies
supportive information about the proportion of patients who
were being treated in the second-line setting at this institution
over the relevant time period. It emphasizes the importance of
performance status as a factor ruling out patients from further
treatment—78% of the patients who were not treated with
second-line chemotherapy were of PS 2 or worse compared
with 40% of the patients who were treated. Indeed in our own
retrospective data presented in poster form at ECCO 2007,
performance status at the start of second-line therapy had a
significant impact on survival with PS 1 patients surviving
10.5 months, PS 2 surviving 5.7 months, and PS 3 surviving
1.2 months (p  0.019).7
Looking to the future, it is possible that the natural
history of SCLC will be changed by these new treatment
approaches. Patients will probably present with different
patterns of relapse now that prophylactic cranial irradiation is
a standard of care, and if they do not get brain metastases they
may maintain their performance status better for further
chemotherapy. In the Froeschl et al. study, the brain was the
first site of relapse in 37.4% of the patients who did not
receive second-line chemotherapy compared with 22.6% of
patients who did. This compares with 35% of patients in the
control arm of the randomized trial of prophylactic cranial
irradiation whereas only 9.1% of the patients who received
irradiation developed brain metastases.4
The current trial suggests that more intensive follow-up of
patients in the month or two after their first line chemotherapy
finishes may allow their relapse to be detected when they are
fitter, and more appropriate for second-line chemotherapy.
A recent retrospective study examined intensive and
“physician directed” follow-up strategies and found the
former lead to no difference in time to diagnosis of recur-
rence, but better response rates and survival in the intensively
followed group, but prospective studies are needed.8 The
availability of an oral agent like topotecan for patients on
relapse could mean more rapid treatment in a situation where
even a few weeks of wait for intravenous chemotherapy can
lead to significant changes in performance status.
The rapid deterioration of many patients on relapse of
their disease shows why this group are difficult to enroll in
trials. New drugs are showing promise. Amrubicin is being
studied in the first-line and relapse setting, as well as for
patients with resistant disease.9 On the other hand, there have
been recent negative phase II trials with bevacizumab, cis-
platin, and irinotecan (response rates of 75%, but median
overall survival of 11.7 months which was no better than a
comparator study of cisplatin and irinotecan alone),10 and a
further negative randomized phase II trial of vandetanib, an
EGFR, and VEGFR inhibitor, versus placebo, showing no
benefit over placebo as maintenance therapy.11 New agents
and approaches for this disease are urgently needed.
We must also not forget the messages from the treatment
of first line SCLC and the use of prophylactic antibiotics and
consider applying them to the relapsed patients who are also at
great risk of infection and death related to neutropenic sepsis.12
In conclusion, while the number of patients with small-
cell lung carcinoma appear to be decreasing,13 after a long
drought in new therapeutic options, our interest is increasing
again!
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